Metastatic Squamous Cell Carcinoma Treated With Pembrolizumab in a Patient With Xeroderma Pigmentosum

A 5-year-old male with xeroderma pigmentosum from Honduras presented with a rapidly growing mass on the left post-auricular neck, associated with left-sided hearing loss. MRI revealed a large mass with invasion of the external auditory canal, temporal bone, and metastasis to lymph nodes. Biopsy confirmed moderately differentiated squamous cell carcinoma (SCC). Given the extensive spread, the patient was started on pembrolizumab, resulting in dramatic clinical and radiographic improvement after four rounds of therapy over 3 months, without associated side effects such as diarrhea, fever, dermatitis, or joint pain. This case demonstrates the effectiveness and tolerability of pembrolizumab in young pediatric patients with metastatic SCC, highlighting its potential as a life-saving treatment for xeroderma pigmentosum patients.

Authors

Institutions

Publication Details

Journal
Pediatric Dermatology
Published
2025-01-16
DOI
https://doi.org/10.1111/pde.15875
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metastatic Squamous Cell Carcinoma Treated With Pembrolizumab in a Patient With Xeroderma Pigmentosum

Sara Choi, Ngan Do, Robert J. Smith, Mary Larijani et al.
Pediatric Dermatology
Cancer Immunotherapy and Biomarkers
article

Metastatic Squamous Cell Carcinoma Treated With Pembrolizumab in a Patient With Xeroderma Pigmentosum

Sara Choi, Ngan Do, Robert J. Smith, Mary Larijani, Maria Queenan
article en

Abstract

A 5-year-old male with xeroderma pigmentosum from Honduras presented with a rapidly growing mass on the left post-auricular neck, associated with left-sided hearing loss. MRI revealed a large mass with invasion of the external auditory canal, temporal bone, and metastasis to lymph nodes. Biopsy confirmed moderately differentiated squamous cell carcinoma (SCC). Given the extensive spread, the patient was started on pembrolizumab, resulting in dramatic clinical and radiographic improvement after four rounds of therapy over 3 months, without associated side effects such as diarrhea, fever, dermatitis, or joint pain. This case demonstrates the effectiveness and tolerability of pembrolizumab in young pediatric patients with metastatic SCC, highlighting its potential as a life-saving treatment for xeroderma pigmentosum patients.

Pediatric DermatologyVol. 42(4)
Children's Hospital of Philadelphia (US), University of Pennsylvania (US)
Openalex Percentile: Top 99%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Metastatic Squamous Cell Carcinoma Treated With Pembrolizumab in a Patient With Xeroderma Pigmentosum — Sara Choi, Ngan Do, et al. · Pediatric Dermatology (2025) | TGRS Research Map | TGRS